Phillip Md Et Al Frost Buys 200,000 Shares of Opko Health, Inc. (OPK) Stock

Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 200,000 shares of the stock in a transaction that occurred on Thursday, June 15th. The stock was purchased at an average price of $6.43 per share, for a total transaction of $1,286,000.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $19,733,354.93. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Tuesday, June 13th, Phillip Md Et Al Frost acquired 7,200 shares of Opko Health stock. The stock was purchased at an average price of $6.51 per share, for a total transaction of $46,872.00.
  • On Monday, June 12th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The stock was purchased at an average price of $6.37 per share, for a total transaction of $11,466.00.
  • On Friday, June 9th, Phillip Md Et Al Frost acquired 25,000 shares of Opko Health stock. The stock was purchased at an average price of $6.39 per share, for a total transaction of $159,750.00.
  • On Wednesday, June 7th, Phillip Md Et Al Frost acquired 55,600 shares of Opko Health stock. The stock was purchased at an average price of $6.27 per share, for a total transaction of $348,612.00.
  • On Tuesday, June 6th, Phillip Md Et Al Frost acquired 30,000 shares of Opko Health stock. The stock was purchased at an average price of $6.30 per share, for a total transaction of $189,000.00.
  • On Monday, June 5th, Phillip Md Et Al Frost acquired 55,000 shares of Opko Health stock. The stock was purchased at an average price of $6.31 per share, for a total transaction of $347,050.00.
  • On Wednesday, May 31st, Phillip Md Et Al Frost acquired 207,700 shares of Opko Health stock. The stock was purchased at an average price of $6.11 per share, for a total transaction of $1,269,047.00.
  • On Tuesday, May 30th, Phillip Md Et Al Frost acquired 18,600 shares of Opko Health stock. The stock was purchased at an average price of $6.28 per share, for a total transaction of $116,808.00.
  • On Friday, May 26th, Phillip Md Et Al Frost acquired 64,600 shares of Opko Health stock. The stock was purchased at an average price of $6.31 per share, for a total transaction of $407,626.00.
  • On Thursday, May 25th, Phillip Md Et Al Frost acquired 26,000 shares of Opko Health stock. The stock was purchased at an average price of $6.38 per share, for a total transaction of $165,880.00.

Opko Health, Inc. (NASDAQ OPK) opened at 6.59 on Tuesday. The stock’s 50 day moving average price is $6.73 and its 200 day moving average price is $8.30. The stock’s market cap is $3.69 billion. Opko Health, Inc. has a one year low of $5.99 and a one year high of $12.15.

Opko Health (NASDAQ:OPK) last announced its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.02. The company had revenue of $296.10 million during the quarter, compared to analysts’ expectations of $313.36 million. Opko Health had a negative return on equity of 2.13% and a negative net margin of 3.60%. Opko Health’s revenue for the quarter was up 1.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.02) EPS. Equities analysts predict that Opko Health, Inc. will post ($0.20) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

COPYRIGHT VIOLATION WARNING: “Phillip Md Et Al Frost Buys 200,000 Shares of Opko Health, Inc. (OPK) Stock” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2655014/phillip-md-et-al-frost-buys-200000-shares-of-opko-health-inc-opk-stock.html.

Several equities research analysts have recently weighed in on the company. Jefferies Group LLC reiterated a “hold” rating and set a $8.00 price target on shares of Opko Health in a research report on Monday, June 12th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $19.50 price target on shares of Opko Health in a research report on Tuesday, June 6th. Standpoint Research reiterated a “buy” rating and set a $14.00 price target on shares of Opko Health in a research report on Sunday, March 5th. Zacks Investment Research cut Opko Health from a “hold” rating to a “sell” rating in a research report on Thursday, May 4th. Finally, Guggenheim assumed coverage on Opko Health in a research report on Tuesday, March 14th. They set a “buy” rating and a $25.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $16.58.

Institutional investors have recently made changes to their positions in the company. Norges Bank bought a new position in shares of Opko Health during the fourth quarter worth approximately $30,421,000. United Capital Financial Advisers LLC boosted its position in shares of Opko Health by 10.6% in the fourth quarter. United Capital Financial Advisers LLC now owns 62,162 shares of the biotechnology company’s stock worth $578,000 after buying an additional 5,934 shares during the period. AQR Capital Management LLC bought a new position in shares of Opko Health during the fourth quarter worth approximately $105,000. Envestnet Asset Management Inc. boosted its position in shares of Opko Health by 23.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 15,355 shares of the biotechnology company’s stock worth $142,000 after buying an additional 2,927 shares during the period. Finally, Folger Hill Asset Management LP bought a new position in shares of Opko Health during the fourth quarter worth approximately $221,000. Hedge funds and other institutional investors own 23.65% of the company’s stock.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:OPK”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.